Vaxcyte, Inc.
PCVX
$54.58
-$1.63-2.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -79.83% | -106.38% | -29.42% | -48.09% | 24.18% |
| Total Depreciation and Amortization | 104.81% | 15.72% | 43.44% | 57.68% | 62.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.07% | 270.34% | -42.13% | 187.51% | 112.94% |
| Change in Net Operating Assets | -692.88% | 9.79% | 532.32% | 32.94% | -106.53% |
| Cash from Operations | -101.82% | -136.06% | 0.19% | -4.49% | 13.52% |
| Capital Expenditure | 71.96% | 68.37% | 74.97% | -121.60% | 47.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 123.44% | 115.16% | 311.21% | 134.18% | -1,321.85% |
| Cash from Investing | 120.66% | 113.21% | 196.69% | 127.34% | -3,900.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -43.01% | -99.98% | -97.08% | -99.26% | 95.50% |
| Repurchase of Common Stock | 7.19% | 57.40% | -55.18% | -- | 72.01% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 60.01% | -60.01% | -- |
| Cash from Financing | -50.93% | -100.24% | -97.72% | -99.91% | 79.41% |
| Foreign Exchange rate Adjustments | -86.96% | 105.22% | 156.74% | -80.67% | 117.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.83% | -104.80% | 56.80% | -119.17% | -348.47% |